RES 529

Drug Profile

RES 529

Alternative Names: P 529; P 52901; Palomid 529; Palomids; RES-529; SG-00529

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Paloma Pharmaceuticals
  • Developer Diffusion Pharmaceuticals; National Cancer Institute (USA)
  • Class Antiepileptic drugs; Antifibrotics; Antineoplastics; Antipsoriatics; Chromans; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Hypoxia-inducible factor 1 inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Proto oncogene protein c-akt inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Glioblastoma; Prostate cancer
  • No development reported Age-related macular degeneration; Atopic dermatitis; Cancer; Diabetic retinopathy; Epilepsy; Proliferative vitreoretinopathy; Psoriasis; Pulmonary fibrosis; Rosacea; Scars

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for preclinical development in Scars in USA (Topical)
  • 24 Jun 2018 Biomarkers information updated
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top